^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    1d
    First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC ) (clinicaltrials.gov)
    P1, N=60, Recruiting, Immunomic Therapeutics, Inc.
    New P1 trial • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative • BRCA mutation
    |
    Keytruda (pembrolizumab)
    1d
    A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) (2025-522643-18-00)
    P2/3, N=137, Recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (clinicaltrials.gov)
    P1, N=300, Enrolling by invitation, M.D. Anderson Cancer Center | Recruiting --> Enrolling by invitation
    Enrollment status
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    1d
    Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=12, Completed, Northwestern University | Recruiting --> Completed | N=100 --> 12
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • carboplatin
    1d
    Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy (clinicaltrials.gov)
    P1, N=0, Withdrawn, Medical College of Wisconsin | N=20 --> 0 | Initiation date: Mar 2026 --> Jun 2026 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal
    |
    Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • ViraferonPeg (peginterferon-α-2b)
    2d
    REVIVE: A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, University of Chicago | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • Libtayo (cemiplimab-rwlc)
    2d
    GALAXIES Lung-301: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=88, Active, not recruiting, GlaxoSmithKline | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Feb 2027 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448)
    2d
    A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases. (PubMed, Medicine (Baltimore))
    The ipilimumab-pembrolizumab combination demonstrated the highest reporting odds ratio (97.2, 95% CI: 58.1-162.4). Integration of pharmacovigilance and transcriptomic data implicates coordinated effects of melanocyte-lineage antigens, innate immune and mitochondrial function pathways in vitiligo pathogenesis. This study aimed to systematically characterize the risk profile, onset timing, and potential biological mechanisms of ICI-induced vitiligo across different treatment strategies and cancer types.
    Retrospective data • Journal • Checkpoint inhibition • Real-world evidence
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab)
    2d
    BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study. (PubMed, Breast Cancer)
    BRCA PV, particularly BRCA1, were strongly associated with pCR in pembrolizumab-treated early TNBC. These findings should be considered hypothesis-generating and warrant confirmation in larger prospective cohorts.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    Keytruda (pembrolizumab)
    2d
    Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction. (PubMed, Expert Rev Pharmacoecon Outcomes Res)
    Pembrolizumab+chemotherapy significantly improved PFS and OS in PD-L1 CPS 1-10 CC patients, with higher mean RMST than the placebo group. However, it is not cost-effective at current prices, but reducing pembrolizumab's price could improve its cost-effectiveness.
    Journal • HEOR • Cost-effectiveness
    |
    PD-L1 (Programmed death ligand 1) • RMST (Rhabdomyosarcoma 2 Associated Transcript)
    |
    Keytruda (pembrolizumab)
    2d
    Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Icahn School of Medicine at Mount Sinai | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial primary completion date
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Prosigna® Breast Risk of Recurrence (ROR) Test • Decipher Prostate Cancer Test
    |
    Keytruda (pembrolizumab) • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • leuprolide acetate for depot suspension
    2d
    Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=73, Active, not recruiting, University of Southern California | Trial completion date: Jun 2026 --> Dec 2027
    Trial completion date
    |
    Keytruda (pembrolizumab) • Stivarga (regorafenib)